Details of the Drug-Related molecule(s) Interaction Atlas

PYRIDINE Drug Info

Azabenzene; 110-86-1; Azine; Pyridin; Pirydyna; Piridina; Pyridin [German]; Pirydyna [Polish]; Piridina [Italian]; RCRA waste number U196; NCI-C55301; Caswell No. 717; CCRIS 2926; HSDB 118; pyridine-ring; CHEBI:16227; FEMA Number 2966; CP 32; UNII-NH9L3PP67S; EINECS 203-809-9; UN1282; NSC 406123; FEMA No. 2966; RCRA waste no. U196; EPA Pesticide Chemical Code 069202; NH9L3PP67S; AI3-01240; pyridine fraction; JUJWROOIHBZHMG-UHFFFAOYSA-N; MFCD00011732; Pentadeuteropyridine; Pyridine [UN1282] [Flammable liquid]; 7291-22-7

Cross-matching ID

PubChem CID

1049

ChEBI ID

CHEBI:16227

CAS Number

CAS 110-86-1

TTD Drug ID

DMF8CJ9

VARIDT Drug ID

DR00680

General Information of Drug (ID: DMF8CJ9)

Molecule-Related Drug Atlas

Molecule Type:

DTT

DOT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Thromboxane-A synthase (TBXAS1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NM-702	DMDJLY9	Angina pectoris	BA40	Phase 3	[7]
E-6700	DMUWJI4	Asthma	CA23	Phase 2	[8]
FK-070	DMJSD5W	Angina pectoris	BA40	Phase 2	[9]
EV-077	DM1FCDH	Type-2 diabetes	5A11	Phase 2	[10]
G-619	DM3H6YC	Thrombosis	DB61-GB90	Phase 1	[11]
NV-52	DM0UOA9	Inflammatory bowel disease	DD72	Phase 1	[12]
Satigrel	DM4LSJ2	Thrombosis	DB61-GB90	Discontinued in Preregistration	[13]
MILACAINIDE TARTRATE	DMJLNUD	Cardiac arrhythmias	BC9Z	Discontinued in Phase 2	[14]
Imitrodast	DMQ2ULV	Asthma	CA23	Discontinued in Phase 2	[15]
Rolafagrel	DM8Q7XV	Nephritis	GB40	Discontinued in Phase 2	[16]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 1A1 (CYP1A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amodiaquine	DME4RA8	Malaria	1F40-1F45	Approved	[17]
Riluzole	DMECBWN	Amyotrophic lateral sclerosis	8B60.0	Approved	[18]
Flutamide	DMK0O7U	Prostate cancer	2C82.0	Approved	[19]
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[20]
Estradiol	DMUNTE3	Acne vulgaris	ED80	Approved	[21]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[22]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[23]
Marinol	DM70IK5	Anorexia nervosa cachexia	6B80	Approved	[24]
Ethinyl Estradiol	DMODJ40	Acne vulgaris	ED80	Approved	[25]
Clofibrate	DMPC1J7	Dysbetalipoproteinemia	5C80.2	Approved	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Fomepizole	DM6VOWQ	Athylene glycol or methanol poisoning	NE61	Approved	[27]
Ademetionine	DMYQDBO	Hepatic fibrosis	DB93.0	Approved	[28]
Theophylline	DMRJFN9	Bronchitis	CA20	Approved	[29]
Rifampicin	DM5DSFZ	Non-insulin dependent diabetes	5A11	Approved	[30]
Ethanol	DMDRQZU	Chronic pain	MG30	Approved	[31]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[32]
Phenobarbital	DMXZOCG	Cluster headache	8A81.0	Approved	[33]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[34]
Didanosine	DMI2QPE	Human immunodeficiency virus infection	1C62	Approved	[29]
Thioridazine	DM35M8J	Schizophrenia	6A20	Approved	[35]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By T-lymphocyte activation antigen CD86 (CD86)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[36]
Nitric Oxide	DM1RBYG	Hypertension	BA00-BA04	Approved	[37]
Kanamycin	DM2DMPO	Bacteremia	1A73	Approved	[6]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[38]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[39]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[40]
Chlorpromazine	DMBGZI3	Acute intermittent hepatic porphyria	5C58.11	Approved	[6]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[41]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[6]
Calcitriol	DM8ZVJ7	Congenital alopecia	LC30	Approved	[42]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Heat shock factor protein 1 (HSF1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[43]
SPI-1005	DM6XFHS	Reperfusion injury	ND56.Z	Approved	[4]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[4]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[44]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[45]
Ceftazidime	DM41GRA	Bacteremia	1A73	Approved	[4]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[40]
Chlorpheniramine	DM5URA2	Allergic rhinitis	CA08.0	Approved	[4]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[4]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[46]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[47]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[48]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[49]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[49]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[50]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[51]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[52]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[53]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[49]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Thromboxane-A synthase (TBXAS1)	TTKNWZ4	THAS_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Gene/Protein Processing	[2]
Cytochrome P450 2E1 (CYP2E1)	OTHQ17JG	CP2E1_HUMAN	Gene/Protein Processing	[3]
Heat shock factor protein 1 (HSF1)	OTYNJ4KP	HSF1_HUMAN	Gene/Protein Processing	[4]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Protein Interaction/Cellular Processes	[5]
T-lymphocyte activation antigen CD86 (CD86)	OTJCSBPC	CD86_HUMAN	Gene/Protein Processing	[6]

------------------------------------------------------------------------------------

References

1	Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives. J Med Chem. 1981 Oct;24(10):1149-55.
2	Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung. Cancer Lett. 2002 Apr 8;178(1):25-36.
3	Essential requirements for substrate binding affinity and selectivity toward human CYP2 family enzymes. Arch Biochem Biophys. 2003 Jan 1;409(1):32-44.
4	A Gene Expression Biomarker Predicts Heat Shock Factor 1 Activation in a Gene Expression Compendium. Chem Res Toxicol. 2021 Jul 19;34(7):1721-1737. doi: 10.1021/acs.chemrestox.0c00510. Epub 2021 Jun 25.
5	Discovery of novel and orally active NR2B-selective N-methyl-D-aspartate (NMDA) antagonists, pyridinol derivatives with reduced HERG binding affinity. Bioorg Med Chem Lett. 2007 Oct 15;17(20):5533-6. doi: 10.1016/j.bmcl.2007.08.039. Epub 2007 Aug 22.
6	A plasmacytoid dendritic cell (CD123+/CD11c-) based assay system to predict contact allergenicity of chemicals. Toxicology. 2009 Oct 1;264(1-2):1-9. doi: 10.1016/j.tox.2009.07.021. Epub 2009 Aug 7.
7	The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol. 2006 Dec 19;48(12):2539-45.
8	Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase. J Med Chem. 1996 Aug 2;39(16):3148-57.
9	Pharmacokinetic and pharmacodynamic properties of FK070 (KDI-792), a novel thromboxane receptor antagonist/thromboxane synthetase inhibitor, after single and multiple oral administrations to healthy volunteers. J Pharm Pharmacol. 1996 Apr;48(4):380-5.
10	Company report (Pharmaceuticalintelligence)
11	G 619, a dual thromboxane synthase inhibitor and thromboxane A2 receptor antagonist, inhibits tumor necrosis factor-alpha biosynthesis. Eur J Pharmacol. 1995 Nov 3;286(1):31-9.
12	Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66.
13	Mechanisms of satigrel (E5510), a new anti-platelet drug, in inhibiting human platelet aggregation. Selectivity and potency against prostaglandin H synthases isozyme activities and phosphodiesterase isoform activities. Biol Pharm Bull. 1996 Jun;19(6):828-33.
14	Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity. J Pharmacol Exp Ther. 1996 Nov;279(2):877-83.
15	RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. Thromb Res. 1988 Sep 1;51(5):507-20.
16	Inhibition by FCE 22178 of platelet and glomerular thromboxane synthase in animal and human kidney disease. Adv Prostaglandin Thromboxane Leukot Res. 1991;21B:707-10.
17	Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
18	Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
19	Anti-androgenic effect of 6-formylindolo[3,2-b]carbazole (FICZ) in LNCaP cells is mediated by the aryl hydrocarbon-androgen receptors cross-talk. Steroids. 2020 Jan;153:108508. doi: 10.1016/j.steroids.2019.108508. Epub 2019 Oct 3.
20	Pharmacologic profiling of human and rat cytochrome P450 1A1 and 1A2 induction and competition. Arch Toxicol. 2008 Dec;82(12):909-21.
21	Effect of CYP1A1 gene polymorphisms on estrogen metabolism and bone density. J Bone Miner Res. 2005 Feb;20(2):232-9. doi: 10.1359/JBMR.041110. Epub 2004 Nov 16.
22	Increased sensitivity for troglitazone-induced cytotoxicity using a human in vitro co-culture model. Toxicol In Vitro. 2009 Oct;23(7):1387-95.
23	Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase. Cancer Res. 1999 Feb 1;59(3):607-14.
24	Gene expression changes in human small airway epithelial cells exposed to Delta9-tetrahydrocannabinol. Toxicol Lett. 2005 Aug 14;158(2):95-107.
25	The metallohormone cadmium modulates AhR-associated gene expression in the small intestine of rats similar to ethinyl-estradiol. Arch Toxicol. 2013 Apr;87(4):633-43.
26	Evidence for a new human CYP1A1 regulation pathway involving PPAR-alpha and 2 PPRE sites. Gastroenterology. 2004 Nov;127(5):1436-45.
27	Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
28	Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
29	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
30	Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
31	An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
32	Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
33	Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
34	Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
35	Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
36	Responsiveness of human monocyte-derived dendritic cells to thimerosal and mercury derivatives. Toxicol Appl Pharmacol. 2010 Jul;246(1-2):66-73. doi: 10.1016/j.taap.2010.04.007. Epub 2010 Apr 22.
37	Regulatory role of nitric oxide on monocyte-derived dendritic cell functions. J Interferon Cytokine Res. 2003 Aug;23(8):423-31. doi: 10.1089/107999003322277838.
38	The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
39	Differential effects of statins on relevant functions of human monocyte-derived dendritic cells. J Leukoc Biol. 2006 Mar;79(3):529-38. doi: 10.1189/jlb.0205064. Epub 2005 Dec 30.
40	Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
41	Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
42	Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol. 2005 Nov;19(11):2685-95.
43	NRF2 transcriptionally activates the heat shock factor 1 promoter under oxidative stress and affects survival and migration potential of MCF7 cells. J Biol Chem. 2018 Dec 14;293(50):19303-19316. doi: 10.1074/jbc.RA118.003376. Epub 2018 Oct 11.
44	Non-steroidal anti-inflammatory drugs inhibit the expression of cytokines and induce HSP70 in human monocytes. Cytokine. 1999 May;11(5):347-58. doi: 10.1006/cyto.1998.0437.
45	Simvastatin induces heat shock factor 1 in vascular endothelial cells. Atherosclerosis. 2006 Oct;188(2):265-73. doi: 10.1016/j.atherosclerosis.2005.10.045. Epub 2005 Dec 20.
46	Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
47	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
48	Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
49	Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
50	Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
51	Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
52	Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
53	Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.